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O R I G I N A L A R T I C L E
Glucocorticoid therapy for adrenal insufficiency: nonadherence,
concerns and dissatisfaction with information
S.C.E. Chapman*, S. Llahana*,†, P. Carroll‡ and R. Horne*
*Centre for Behavioural Medicine, Research Department of Practice and Policy, UCL School of Pharmacy, †Department of
Endocrinology, University College Hospital, and ‡Guys and St Thomas’ NHS Foundation Trust, London, UK
Summary
Objective Appropriate self-management of glucocorticoid ther-
apy (GC) is crucial for patients with adrenal insufficiency (AI).
We aimed to describe patients’ self-reported nonadherence to
GC, evaluate perceived doubts about need for GC, concerns
about adverse effects, and dissatisfaction with information
received about GC.
Design Cross-sectional survey.
Patients Patients prescribed GC for AI (n = 81) from five
European countries.
Measurements Online survey including the Medication
Adherence Report Scale (MARS), Beliefs about Medicines
Questionnaire© (BMQ Specific, adapted for AI) and Satisfaction
with Information about Medicines Scale© (Prof Rob Horne;
SIMS).
Results Most patients (852%) reported a degree of nonad-
herence to GC. The most frequent types of nonadherence con-
cerned changing the timing of GC doses, for example taking a
dose later in the day than advised (370%). Few patients
doubted their personal need for daily GC, but most reported
high concerns about GC including potential weight gain
(506%), osteoporosis (536%) and the continuing risk of
adrenal crisis (506%). Dissatisfaction with information about
GC was frequent, with participants particularly dissatisfied
with the amount of information they had received about
potential problems with GC. People who expressed dissatisfac-
tion with information about GC, and concerns about its
adverse effects were also more likely to report nonadherence
(P < 005).
Conclusions Nonadherence to treatment, concerns about
potential adverse effects and dissatisfaction with the information
provided about treatment were frequently reported by this Euro-
pean sample of AI patients. Many AI patients may need addi-
tional information about their GC and support to address
concerns about GC and facilitate adherence.
(Received 9 September 2015; returned for revision 2 November
2015; finally revised 25 November 2015; accepted 26 November
2015)
Introduction
A replacement medication regimen including glucocorticoid and
mineralocorticoids is essential for patients with adrenal insuffi-
ciency (AI).1 However, some patients do not take their treat-
ment as prescribed putting them at risk of adrenal crises and ill
health.2,3 Existing steroid replacement regimens are complex and
usually require patients to take medication at specific times of
the day to mimic normal physiological cortisol rhythm.3 Educa-
tion is important, and patients learn how to increase their medi-
cation in response to physiological exertion, psychological stress
and minor illness.1,4 Despite recognition by patients and practi-
tioners of the importance of adherence to glucocorticoid therapy
(GC) replacement, little is known about the adherence of
patients to GC treatment and less about why patients may not
take medication in the optimal way.
Few studies have addressed adherence in patients with AI.
One recent survey of 116 Dutch AI patients found that reported
adherence to treatment advice was suboptimal in three domains:
adherence to medication, preparedness for an adrenal crisis (e.g.
carrying an ampoule of hydrocortisone) and dose adaptation in
medical emergencies.5 Reasons for nonadherence are complex
and may not always be recognized by clinicians. For those
involved in clinical patient management and HCPs advising on
treatment regimens an understanding of patient’s perceptions is
important. Despite this, few studies have explored AI patients’
perceptions of treatment and adherence using the validated
questionnaires often used to assess these factors in other long-
term conditions. A single published study assessed patients’
beliefs about medications used to treat AI and found that
patients were often concerned about the potential adverse effects
of their medication.6 Across over 23 other long-term conditions
(e.g. HIV, asthma, diabetes, hypertension), doubts about per-
sonal need for treatment and concerns about treatment have
been frequently linked to nonadherence, with those with greater
concerns being less likely to adhere to their prescribed treatment
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regimen.7 However, no studies have explored the relationship
between adherence to treatment, beliefs about treatment and
information in AI.
This study uses validated questionnaire methods to explore
perceptions of GC (perceived need for treatment and concerns
about adverse effects) and reported nonadherence in AI. Because
information provision may be one way to address concerns and
enable patients to adhere, for example if they receive education
on adverse effect risks and how to take their medication, we also
use a validated scale to assess satisfaction with information
about GC. As adherence to GC medication requires not only
taking a certain number of doses (dose adherence) but also
requires that these doses are taken at particular times (timing
adherence), we also examined patients’ reports of their adher-
ence to each of these different aspects of adherence.
Recognizing that understanding reasons behind nonadherence
is essential in the management of patients with AI, this study
addressed the following aims:
1 To identify the prevalence and nature of self-reported nonad-
herence (including both dose adherence and timing adherence)
2 To understand AI patients’ perceptions of GC and satisfaction
with information that they have received about GC
3 To test whether reported nonadherence is correlated with neg-
ative views about GC (doubts about GC necessity, GC concerns
and dissatisfaction with information about GC).
Method
Design
This is a cross-sectional survey of AI patients, in which ques-
tionnaires validated for assessing patients’ perceptions of treat-
ment and reported adherence to treatment in other long-term
conditions were adapted for use in AI.
Recruitment
Participants were recruited in May 2013 across five European
countries (UK, Germany, Sweden, France and Spain) through
convenience sampling. Patient support groups (e.g. the Pituitary
Foundation and Addison’s Disease Network) and endocrinology
consultants were asked to make AI patients known to them
aware of the opportunity to participate in the study, including
being provided with the contact details of the research team.
Patients already registered with market research databases were
also contacted. Where possible, posts were made on social media
and patient forums to raise awareness of the study. Patients who
made contact with the research team were screened by a market
researcher to ensure they met the inclusion/exclusion criteria;
eligible patients were sent a link to the online survey. All partici-
pants who assessed as being eligible by the screening procedure
participated in and completed the survey. The Market Research
Society (MRS) approved the patient enrolment procedure. Con-
sent was obtained using an online form immediately prior to
data collection. Participants were paid for completing the survey:
UK: £35, France €25, Germany €45, Italy €40, Spain €40 and
Sweden 200kr.
Inclusion/exclusion criteria
Participants were included if they were aged between 18 and
70 years, diagnosed with either primary AI (Addison’s Disease),
Secondary AI or Congenital Adrenal Hyperplasia (CAH). All
participants had been diagnosed for more than 6 months, were
taking hydrocortisone immediate release tablets (once, twice or
three times daily), once-daily modified release hydrocortisone or
cortisone acetate (once, twice or three times daily) for AI, with a
sample quota of 50% to have been on treatment for 12 months
or over. All participants also had computer access as needed to
complete the survey.
Measures
Demographic and clinical information. Participants were asked to
report their age, gender, type of AI (primary AI, secondary AI
or CAH), and how many years they have been diagnosed with
AI. Regarding their medication, participants were asked to
describe their current GC, including the length of time they had
been taking it. We also asked participants to report: recent days
of illness and healthcare seeking; whether they had
hypothyroidism, osteoporosis, type 1 diabetes, vitamin B12
deficiency or coeliac disease; and what medications they were
taking for these or other comorbid conditions.
Adherence to steroid replacement therapy (GC). Participants rated
their adherence to GC on an 8-item Medication Adherence
Report Scale (MARS)© (Prof Rob Horne), modified for AI.8
The four core items of the MARS were supplemented with four
AI-specific items generated in discussion with clinicians and
patients who formed the advisory panel. The revised 8-item
scale had adequate internal reliability in the current sample
(Cronbach’s a = 086). Two subscales, one comprised of the five
items concerning nonadherence to number of doses (Dose
Adherence) and one comprised of the three items concerning
deviations from the prescribed timing of doses (Timing
Adherence), were used to describe the nature of nonadherence.
Participants rated the frequency with which they performed each
type of nonadherent behaviour on a 5-point scale (5 = never,
4 = rarely, 3 = sometimes, 2 = often and 1 = very often). Scores
were summed to give a total score (range 8–40); higher scores
indicate higher reported adherence.
To describe adherence, total scores and subscale scores were
used to split participants in two ways: (i) full adherence
(reporting no nonadherent behaviours) vs any reported nonad-
herence and (ii) high adherence (scoring more than 32, i.e.
80%) vs low adherence (scoring 32 or less). Individual item
responses were also dichotomized (low adherence = sometimes,
often or very often; high adherence = never, rarely), to provide
an indication of the prevalence of each nonadherent
behaviour.
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Perceptions of GC. The Beliefs about Medicines Questionnaire
(BMQ)©-Specific scale,9 modified for AI was used to measure
participants’ beliefs about GC. The modified BMQ AI Specific©
comprises: (i) a 5-item GC-Necessity subscale assessing the
participant’s views about their personal need for the GC
medication; and (ii) an 11-item GC-Concerns subscale assessing
participants’ concerns about the potential adverse consequences
of taking GC. The GC-Concerns subscale was adapted for AI
with additional items about side effects, osteoporosis, weight
gain, sleep, viewing GC as a reminder of AI and adrenal crises.
For each BMQ statement, participants indicated their agreement
on a 5-point Likert scale (range 1 = strongly disagree to
5 = strongly agree). GC-Necessity and GC-Concerns scores
were computed by summing all subscale responses, then
dividing by the number of items (range 1–5). In the current
sample, both scales had good internal reliability (both
Cronbach’s a’s = 086). To describe the frequency of individual
concerns and doubts about GC necessity, we categorized
participants on each GC-Necessity item (strongly disagree/
disagree/uncertain = doubt; agree/strongly agree = no doubt)
and GC-Concern item (agree/strongly agree = concern; strongly
disagree/disagree/uncertain = no concern).
Satisfaction with information about GC. Participants completed
the validated Satisfaction with Information about Medicines
Scale© (SIMS),10 to indicate their satisfaction with the
information they had received about their GC. The SIMS has
two subscales. The first assesses satisfaction with the information
received about the Action and Usage of GC: about how it works
and should be used, for example how to refill a prescription
(SIMS AU 9-items). The second assesses satisfaction with
information about dealing with Potential Problems associated
with GC, for example adverse effects and interactions, (SIMS PP
8-items). For each subscale item, participants stated whether
they were satisfied with the amount of information they had
received (about right, none needed) or dissatisfied (too much,
too little, none received). Subscale scores were calculated by
counting the total number of ‘satisfied’ responses.
Statistical analyses
Descriptive statistics (means, standard deviations (SD) and fre-
quencies) are used to describe responses to all items. Correla-
tions are used to test for associations between BMQ, SIMS and
MARS scales, and between MARS scores and participant age and
time since diagnosis. Chi-square test is used to describe associa-
tions between categorized MARS scores and categorical variables
(gender, type of AI, dose frequency).
Results
Demographics and patient characteristics
The sample comprised 81 participants from the UK (n = 20),
France (n = 20), Sweden (n = 15), Spain (n = 16) and Germany
(n = 10). All participants who expressed interested in taking part
completed the survey. The mean age of the sample was
473 years (SD = 144 years). The sample was approximately
two-thirds female (679%, n = 55).
Most participants had Primary AI. The mean length of time
since diagnosis of AI was 122 years (SD = 87 years). Slightly
under half of the sample reported at least one comorbid condi-
tion (see Table 1). Just over half the participants (519%,
n = 42) reported that they had missed one or more days from
study or work or had been unable to carry out their normal
daily activities due to illness in the last year. Just under a quarter
(222%, n = 18) had been to hospital due to an adrenal crisis in
the past year, most of these (n = 13) on one occasion. The
majority of these patients (n = 12, 148%) had only been to hos-
pital on one occasion.
Most participants were taking twice (457%, n = 37) or three
times daily (370%, n = 30) doses of hydrocortisone tablets. Ele-
ven participants (136%) were taking modified-release, once daily
hydrocortisone tablets. Only seven participants (86%) had chan-
ged their medication in the previous 2 years. Most (630%,
n = 51) participants reported they had increased their GC dose in
the past year due to illness. Over a third had increased their dose
on 1–4 occasions (383%, n = 31), 173% (n = 14) had increased
their dose 5–10 times and 74% (n = 6) had increased their dose
more than 10 times. Approximately a quarter of the sample had
been to hospital to receive intravenous hydrocortisone (247%,
n = 20) and just under one in ten had self-administered intra-
muscular hydrocortisone in the past year (86%, n = 7). Of the
17 participants with Secondary AI, nine indicated they were tak-
ing thyroxine treatment for TSH deficiency, two were taking
testosterone replacement therapy for gonadotropin deficiency,
and four had growth hormone deficiency on replacement.
Prevalence and nature of nonadherence to GC
Only 12 (148%) reported full adherence, that is that they never
took their medication in a way that was different to how it had
Table 1. Clinical characteristics of the sample
n (%)
Type of adrenal insufficiency (AI)
Primary (Addison’s disease, congenital
adrenal hyperplasia, autoimmune
polyglandular syndrome)
64 (790%)
Secondary (caused by pituitary or
hypothalamic disorder)
17 (210%)
Length of time with AI
1–5 years 24 (296%)
6–10 years 17 (210%)
11–20 years 26 (321%)
21 or more years 14 (173%)
Comorbid conditions
Hypothyroidism 31 (383%)
Osteoporosis 8 (99%)
Type 1 diabetes 6 (74%)
Vitamin B12 deficiency 6 (74%)
Coeliac disease 2 (25%)
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2016), 84, 664–671
666 S.C.E. Chapman et al.
been prescribed. Approximately one-third of participants
(346%, n = 28) were in the low adherence group and (654%,
n = 53) were classed as high adherers. This nonadherence arose
from both dose and timing nonadherence; 790% of our sample
reported any dose nonadherence (n = 64), and 667% (n = 54)
reported any timing nonadherence. The most frequently
reported individual nonadherent behaviours were associated
with timing of doses. Over a third (370%, n = 26) said that
they sometimes, always or often took their dose later in the day
than advised, and 346% (n = 28) said that they sometimes,
always or often took their dose at a different time of day than
advised (see Fig. 1).
Perceptions of GC and satisfaction with information
about GC
GC necessity beliefs. Participants’ responses indicated that they
were largely convinced of their personal need for their GC
(BMQ Necessity mean = 461, SD = 066, scores near five
indicate high Necessity). When responses to the individual items
were assessed, the highest proportion of doubts were for the
statement ‘my health in the future will depend on my
medicines’, which 160% (n = 13) of respondents expressed
doubt about. However, fewer than 10% of participants reported
doubts about any other Necessity item, indicating that
participants were typically strongly convinced of their current
need for their medication (see Fig. 2).
GC concerns. Concerns about the possible adverse consequences
of AI medication were prevalent (BMQ Concerns mean = 289,
SD = 083, scores near one indicate high Concern). Most
strikingly, 556% (n = 45) said that they ‘sometimes worry
about the long-term effects of this medication’; 531% (n = 43)
agreed that they ‘worry about medication causing osteoporosis’;
506% (n = 41) said that they worry that their medication
‘might cause weight gain’; and 506% (n = 41) said that they
‘worry about having an adrenal crisis despite taking my
medication’ (see Fig. 3).
Satisfaction with information about GC. Participants were more
dissatisfied with the amount of information they had received
about potential problems with their GC (SIMS PP mean
number of items rated as ‘dissatisfied’ = 394, SD = 284), than
with the amount of information they received about the action
and use of their GC (SIMS AU mean number of items rated
as ‘dissatisfied’ = 279, SD = 308). Nearly two-thirds of
participants were dissatisfied with the level of information they
had received about the risks of getting side effects (617%,
n = 50) and whether the medicine has unwanted side effects
(593%, n = 48). More than half were dissatisfied with the
amount of information they had received about whether they
should drink alcohol while taking their AI medication (543%,
n = 44), what they should do if they experience unwanted side
effects (556%, n = 45), and about possible interactions with
other medications (543%, n = 44) (see Fig. 4).
Was reported nonadherence associated with clinical and
demographic factors?
Demographic factors were associated with adherence, such that
women were more likely to report low adherence than men,
418% of female participants reported low adherence compared
to 192% of male participants v2(1, n = 81) = 398, P = 005,
and age was associated with adherence such that older partici-
pants were more adherent, r(81) = 045, P < 0001. The distri-
bution of adherence scores was similar across participants who
did and did not report comorbidities and those reported pri-
mary vs secondary AI (ps > 005). To investigate the impact of
dosing frequency, we compared MARS scores in participants
who reported taking one or two doses of GC each day with par-
ticipants who reported three or more daily doses using a Mann–
Whitney U-test. Participants who reported one or two daily
doses were more adherent than participants who took 3 or more
doses U = 51850, P = 004.
Was reported nonadherence associated with doubts
about GC necessity, GC concerns and dissatisfaction with
information about GC?
To test whether reported nonadherence is associated with nega-
tive views about GC (doubts about GC necessity, GC concerns
and dissatisfaction with information about GC), Spearman’s
correlations were computed between MARS scores, BMQ scores
and SIMS scales. Higher reported nonadherence on the MARS
Fig. 1 Prevalence of nonadherent behaviours based
on proportion of participants who report that they
‘sometimes, often or always’ took their regimen in
ways other than advised when responding to the
MARS scale.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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was significantly associated with more GC Concerns and more
dissatisfaction with information (SIMS AU and SIMS PP; see
Fig. 5). GC Necessity was not significantly associated with
adherence.
Discussion
This study is the first to examine AI patients’ adherence to GC
and to explore associations between adherence and perceptions
of treatment. We found only 128% reported full adherence. Few
patients doubted their personal need for daily GC, but many had
strong concerns about the potential adverse effects of GC and
were dissatisfied with the amount of information about GC they
had received. People who were dissatisfied with the amount of
information they had received and concerned about the potential
negative effects of GC reported more nonadherence to GC.
Significant numbers of participants reported nonadherent
behaviours, with fewer than 15% of patients reporting they
always took their medication as prescribed. Analysis of the
MARS item scores indicated particular difficulties with taking
treatment on time, with a third of patients reporting they var-
ied their medication schedule and a third stating that they
delayed doses. Out findings supplement existing literature
which suggests that patients may forget daily doses11 and that
adjusting doses when at risk of adrenal crisis may be a partic-
ular challenge for patients.5 This indicates that even when
patients are taking the recommended number of doses they
may be taking a proportion of these doses off-schedule. Non-
adherence to GC may place participants at risk for avoidable
morbidity and mortality. Under-replacing hydrocortisone can
lead to potentially fatal adrenal crises, whereas over-replacing
hydrocortisone can lead to Cushing’s-like symptoms.12 Clinical
judgement is needed to ensure that corticosteroid regimens
ensure that patients’ appetite and energy levels are regulated
correctly, and dose timing is a key factor in this process.13 It
is possible therefore that this nonadherence to both the dose
Fig. 2 Doubts about need for glucocorticoid
therapy (GC). Percentage of respondents endorsing
‘uncertain’, ‘disagree’ or ‘strongly disagree’ to
statements about their personal need for their GC.
Fig. 3 Glucocorticoid therapy (GC) concerns. Percentage of respondents endorsing ‘agree’ or ‘strongly agree’ to statements about concerns about GC.
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and timing of GC may increase the impact of AI, leading to
weight gain and fatigue.
Glucocorticoid therapy necessity scores were high (mean 461
of 5), indicating participants were convinced GC was important
for ensuring their current and future health. Most participants
reported significant concerns about GC including weight gain,
osteoporosis, potential long-term adverse effects and risk of
adrenal crisis, which were all reported by more than 50% of par-
ticipants. These high concerns are similar to those reported in
other patients taking GC.14 In line with the predictions of the
Necessity-Concerns Framework,7,9,15 our findings suggest that
even adherent patients may be worried about their GC, and that
for some patients, these concerns lead to nonadherence.
Dissatisfaction with information provided about GC adverse
effects appeared to be particularly common in our sample, with
participants reporting dissatisfaction with, on average, more than
three aspects of information about potential problems with their
medication. Participants who were more dissatisfied with the
amount of information they had received about their GC had
higher concerns and reported more nonadherence. Given the
cross-sectional nature of the study, it is not possible to identify
cause and effect relationships. However, it is likely that dissatis-
faction with information about side effects and concerns might
be mutually reinforcing, such that a lack of information about
side effects may represent a missed opportunity to reassure
patients and alleviate their concerns, while patients who have
high concerns may tend to be more dissatisfied with the current
standard of information.
Some demographic and clinical factors were associated with
nonadherence in out sample. Younger participants, women and
Fig. 4 Dissatisfaction with information about
glucocorticoid therapy (GC) on the Satisfaction
with Information about Medicines Scale (SIMS).
Participants who stated that they had received ‘too
much’, ‘too little’ or ‘none received’ were classed as
dissatisfied.
Fig. 5 Correlation between concerns about
medication, satisfaction of information about
medicines and adherence.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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people who were prescribed more than two doses per day of GC
were at the highest risk for nonadherence. These findings are
difficult to interpret given our small sample size, cross-sectional
design and the number of potential uncontrolled confounding
factors, and need further investigation. However, they do suggest
that for some patients, simplifying their medication regimen
may support adherence. There were no significant differences
between participants with primary and secondary AI, possibly
because the treatment regimens are similar; however, again it is
difficult to draw strong conclusions about this finding.
The current study has several limitations. The sample size was
too small to detect moderate–small associations between variables
or investigate heterogeneity or small subgroups within the sam-
ple. We used patient support groups and social media to adver-
tise the survey, and so do not know what proportion of people
who saw the survey advertisements responded, potentially mean-
ing that our sample was biased towards people who were inter-
ested in issues around their medication. As the survey was cross-
sectional, caution is needed before concluding there are causal
relationships between the factors. As a self-report study, there
may be differences between patients’ actual behaviour or, for
example, the information they had received, and those that they
have reported in this study. Available objective adherence mea-
sures, for example electronic monitoring,16 pharmacy refill
records,17 and pill count,18 could not be used to validate reported
adherence because of the online survey nature of this study.
Despite these limitations, this is, to our knowledge, the first
study to evaluate adherence, perceptions of GC and perceptions
of GC information using validated measures in AI. Our results
show that AI patients have a diverse range of views on their GC.
Understanding reasons behind nonadherence and effective
medicines use is important for clinicians in helping patient s
with long-term conditions effectively self-manage. This study
indicates that concerns about potential adverse effects from GC
use are very important for patients with AI and influence
medicines usage. Strategies to facilitate optimal adherence to GC
should support both dosage adherence and timing adherence
and should be tailored to the needs of the individual addressing
their specific concerns and information needs.
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